- Home
- FRME vs IBRX Comparison
FRME vs IBRX Comparison
Compare FRME & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRME
- IBRX
- Stock Information
- Founded
- FRME 1893
- IBRX 2014
- Country
- FRME United States
- IBRX United States
- Employees
- FRME N/A
- IBRX N/A
- Industry
- FRME Major Banks
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FRME Finance
- IBRX Health Care
- Exchange
- FRME Nasdaq
- IBRX Nasdaq
- Market Cap
- FRME 2.4B
- IBRX 2.6B
- IPO Year
- FRME N/A
- IBRX N/A
- Fundamental
- Price
- FRME $39.07
- IBRX $2.90
- Analyst Decision
- FRME Buy
- IBRX Strong Buy
- Analyst Count
- FRME 5
- IBRX 5
- Target Price
- FRME $47.50
- IBRX $11.35
- AVG Volume (30 Days)
- FRME 240.4K
- IBRX 6.5M
- Earning Date
- FRME 04-24-2025
- IBRX 03-03-2025
- Dividend Yield
- FRME 3.58%
- IBRX N/A
- EPS Growth
- FRME N/A
- IBRX N/A
- EPS
- FRME 3.41
- IBRX N/A
- Revenue
- FRME $610,994,000.00
- IBRX $14,745,000.00
- Revenue This Year
- FRME $17.27
- IBRX $753.44
- Revenue Next Year
- FRME $3.93
- IBRX $174.29
- P/E Ratio
- FRME $11.47
- IBRX N/A
- Revenue Growth
- FRME N/A
- IBRX 2270.58
- 52 Week Low
- FRME $30.55
- IBRX $2.28
- 52 Week High
- FRME $46.13
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- FRME 32.50
- IBRX 44.87
- Support Level
- FRME $38.80
- IBRX $2.73
- Resistance Level
- FRME $44.33
- IBRX $3.16
- Average True Range (ATR)
- FRME 1.20
- IBRX 0.26
- MACD
- FRME -0.55
- IBRX -0.03
- Stochastic Oscillator
- FRME 4.88
- IBRX 24.69
About FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.